A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

Active:	No
Cancer Type:	Breast Cancer Solid Tumor Unknown Primary	NCT ID:	NCT05307705
Trial Phases:	Phase I	Protocol IDs:	LOXO-PIK-21001 (primary) NCI-2022-04290 2022-000175-40 J4C-OX-JZUA
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT05307705

Summary

The main purpose of this study is to learn more about the safety, side effects, and
effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid
tumors that have a change in a particular gene (known as the PIK3CA gene). Participation
could last up to 36 months (3 years) and possibly longer if the disease does not get
worse.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.